Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035331) PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/035331 International Application No.: PCT/US2016/048643
Publication Date: 02.03.2017 International Filing Date: 25.08.2016
IPC:
A61K 31/155 (2006.01) ,A61K 31/19 (2006.01) ,A61K 31/195 (2006.01)
[IPC code unknown for A61K 31/155][IPC code unknown for A61K 31/19][IPC code unknown for A61K 31/195]
Applicants:
RGENIX, INC. [US/US]; 310 East 67th Street, Suite 1-12 New York, NY 10065, US
Inventors:
MARTINEZ, Eduardo, J.; US
GRILL, Andreas, G.; US
SINGH, Aniruddh; US
KAVURU, Padmini; US
Agent:
BIEKER-BRADY, Kristina; US
Priority Data:
62/209,62425.08.2015US
Title (EN) PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
(FR) SELS PHARMACEUTIQUEMENT ACCEPTABLES D'ACIDE BÊTA-GUANIDINOPROPIONIQUE AYANT DES PROPRIÉTÉS AMÉLIORÉES ET UTILISATIONS DE CEUX-CI
Abstract:
(EN) The present invention relates to new pharmaceutical salts of β-GPA which exhibit improved physical properties. In particular, the invention relates to salts of β-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of β-GPA, as well as methods of treating cancer including administration of a formulation including a β-GPA salt of the invention to a subject in need thereof.
(FR) La présente invention concerne de nouveaux sels pharmaceutiques de β-GPA qui présentent des propriétés physiques améliorées. En particulier, l'invention concerne des sels de β-GPA ayant des propriétés d'écoulement améliorées (par exemple, un indice de Carr et/ou un rapport de Hausner améliorés) tels que des sels de fumarate, des sels de succinate et des sels d'oxalate. L'invention concerne en outre des compositions pharmaceutiques comprenant une quantité pharmaceutiquement efficace d'un ou de plusieurs sels de β-GPA, ainsi que des procédés de traitement du cancer comprenant l'administration d'une formulation comprenant un sel de β-GPA de l'invention à un sujet en ayant besoin.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)